(Q44136733)
Statements
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies (English)
Alison Stopeck
Marrae Sheldon
Mahmood Vahedian
Gillian Cropp
Rishi Gosalia
1 September 2002